We are live on
!
Find out more
SEC
Seven Eight Capital Portfolio holdings
AUM
$1.11B
1-Year Est. Return
29.48%
This Fund
S&P 500
This Quarter
Est. Return
-6.56%
1 Year Est. Return
+29.48%
3 Year Est. Return
+13.61%
5 Year Est. Return
+117.69%
10 Year Est. Return
+239.1%
AUM
$855M
AUM Growth
+$250M
(+41%)
Cap. Flow
+$327M
Cap. Flow
% of AUM
38.29%
Top 10 Holdings %
Top 10 Hldgs %
13.1%
Holding
788
New
316
Increased
155
Reduced
106
Closed
211
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edwards Lifesciences
EW
|
+$13.6M |
| 2 |
Merck
MRK
|
+$12.5M |
| 3 |
Intuitive Surgical
ISRG
|
+$11.1M |
| 4 |
DOCU
DocuSign
DOCU
|
+$10.9M |
| 5 |
Insulet
PODD
|
+$10.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nasdaq
NDAQ
|
+$7.26M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
+$6.86M |
| 3 |
Incyte
INCY
|
+$6.31M |
| 4 |
Fidelity National Information Services
FIS
|
+$5.73M |
| 5 |
AbbVie
ABBV
|
+$4.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.41% |
| 2 | Consumer Discretionary | 17.68% |
| 3 | Healthcare | 16.13% |
| 4 | Industrials | 12.13% |
| 5 | Financials | 8.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
lululemon athletica
LULU
$14B
| $973K | 0.11% |
2,523
-3,293
| -57% | -$1.26M |
|
252
Warrior Met Coal
HCC
$4.25B
| $964K | 0.11% |
+18,880
| New | +$792K |
|
253
Progyny
PGNY
$2.47B
| $958K | 0.11% |
+28,164
| New | +$1.06M |
|
254
Aramark
ARMK
$14.9B
| $956K | 0.11% |
+52,867
| New | +$1.48M |
|
255
Dana Inc
DAN
$2.97B
| $956K | 0.11% |
+65,166
| New | +$1.09M |
|
|
FL
256
DELISTED
Foot Locker
FL
| $946K | 0.11% |
54,536
+31,185
| +134% | +$697K |
|
257
NetEase
NTES
$84.2B
| $946K | 0.11% |
+9,443
| New | +$968K |
|
258
Hubbell
HUBB
$25.2B
| $941K | 0.11% |
3,004
-16
| -0.5% | -$5.09K |
|
259
Hilton Worldwide
HLT
$70.7B
| $939K | 0.11% |
+6,250
| New | +$944K |
|
260
Advanced Drainage Systems
WMS
$11.5B
| $937K | 0.11% |
+8,232
| New | +$1.01M |
|
261
A.O. Smith
AOS
$8.25B
| $919K | 0.11% |
13,902
+4,496
| +48% | +$319K |
|
262
Tradeweb Markets
TW
$21.5B
| $915K | 0.11% |
+11,413
| New | +$910K |
|
263
Helix Energy Solutions
HLX
$1.36B
| $915K | 0.11% |
+81,919
| New | +$789K |
|
264
HF Sinclair
DINO
$15.8B
| $914K | 0.11% |
+16,054
| New | +$872K |
|
265
Reliance Steel & Aluminium
RS
$20.9B
| $913K | 0.11% |
+3,482
| New | +$965K |
|
266
EQT Corp
EQT
$33.5B
| $911K | 0.11% |
+22,461
| New | +$930K |
|
267
DHT Holdings
DHT
$2.98B
| $911K | 0.11% |
88,471
+55,358
| +167% | +$518K |
|
268
Pinterest
PINS
$14.3B
| $902K | 0.11% |
33,383
-155,709
| -82% | -$4.25M |
|
269
Corteva
CTVA
$50.7B
| $895K | 0.1% |
17,493
-48,024
| -73% | -$2.54M |
|
270
Rockwell Automation
ROK
$49.5B
| $890K | 0.1% |
+3,113
| New | +$963K |
|
271
Brown-Forman Class B
BF.B
$12.8B
| $888K | 0.1% |
15,385
+6,108
| +66% | +$406K |
|
|
PPLI
272
People Inc
PPLI
$3.13B
| $883K | 0.1% |
+21,362
| New | +$1.04M |
|
|
SAGE
273
DELISTED
Sage Therapeutics
SAGE
| $877K | 0.1% |
+42,632
| New | +$1.23M |
|
|
B
274
Barrick Mining
B
$64B
| $871K | 0.1% |
+59,866
| New | +$981K |
|
275
Texas Roadhouse
TXRH
$13.8B
| $870K | 0.1% |
+9,053
| New | +$964K |
|
Similar funds
PP
ECM
GCAC
CAM
D
GFS
FTIS
AIA
Seven Eight Capital's Q3 2023 Portfolio in Review
As of Q3 2023, Seven Eight Capital held 788 positions worth $855M, up 41% from $605M the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Seven Eight Capital deployed $327M of net new capital in Q3 2023, opening 316 new positions and adding to 155 existing holdings. Its largest new stake was Merck: 115,677 shares worth $11.9M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 22% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $6.86M trimmed.
- Seven Eight Capital's largest Q3 2023 buy was Merck: 115,677 shares worth $11.9M.
- Seven Eight Capital added most to Edwards Lifesciences in Q3 2023, an estimated $13.6M increase.
- Seven Eight Capital's biggest Q3 2023 reduction was BioMarin Pharmaceuticals, cutting an estimated $6.86M.
- Seven Eight Capital fully exited Nasdaq in Q3 2023, selling an estimated $7.26M.
- Seven Eight Capital's ten largest holdings make up 13% of its $855M portfolio in Q3 2023.
- Seven Eight Capital opened 316 new positions and closed 211 in Q3 2023.
- Seven Eight Capital's portfolio value rose 41% quarter-over-quarter to $855M.
Based on Seven Eight Capital's 13F filing for Q3 2023, filed 14 Nov 2023.